Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05911763 · ClinicalTrials.gov registry record
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
A clinical trial of Hemophilia A, sponsored by Sanofi.
- Active
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT05911763: Active study of Hemophilia A, sponsored by Sanofi.
NCT05911763 is a study of Hemophilia A that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 200 participants, above the 87-participant average among 42 other Hemophilia A trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05911763, a study of Hemophilia A, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating physician independently from the decision to include patients in the study. No study medication is provided. The data related to efanesoctocog alfa effectiveness, safety and usage will be collected prospectively during routine visits (expected annual/semi-annual visits) for up to 5 years following enrollment /treatment initiation.
Primary Outcome
Data will be reported for the effectiveness of efanesoctocog alfa prophylaxis on clinical joint status over 5-years for prophylactic cohort
Conditions Studied
Interventions
- DRUG Efanesoctocog Alfa BIVV001
Study Locations (20)
California
- Loma Linda University- Site Number : 8400015 - Loma Linda
- Orthopedic Institute for Children- Site Number : 8400004 - Los Angeles
- The Center for Inherited Blood Disorders- Site Number : 8400001 - Orange
Florida
- William A. Shands Hospital at the University of Florida- Site Number : 8400032 - Gainesville
- Johns Hopkins All Childrens Hospital - Outpatient Care Center - PIN- Site Number : 8400025 - St. Petersburg
Illinois
- Rush University Medical Center -1725 W Harrison St- Site Number : 8400014 - Chicago
- The Bleeding and Clotting Disorders Institute- Site Number : 8400005 - Peoria
Massachusetts
- ~Massachusetts General Hospital- Site Number : 8400017 - Boston
- Dana Farber and Boston Children's Hospital- Site Number : 8400031 - Boston
Minnesota
- M Health Fairview- Masonic Cancer Clinic - Clinics- Site Number : 8400010 - Minneapolis
- Mayo Clinic - PPDS- Site Number : 8400035 - Rochester
Arizona
- Banner MD Anderson Cancer Center- Site Number : 8400008 - Gilbert
Colorado
- University of Colorado Hemophilia and Thrombosis Center- Site Number : 8400019 - Aurora
Indiana
- Indiana Hemophilia and Thrombosis Center- Site Number : 8400013 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2030-09-17 |
What the registry record for NCT05911763 still lists
NCT05911763 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 87-participant average among 42 other Hemophilia A trials with a reported enrollment target (130% higher).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Efanesoctocog Alfa BIVV001 is the first listed.
NCT05911763 names 20 study sites across 14 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05911763 about?
NCT05911763 is a clinical study titled "A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A". This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the in...
What is the current status of trial NCT05911763?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2023-06-30. Estimated completion is 2030-09-17.
What conditions does trial NCT05911763 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT05911763?
The interventions under investigation include: Efanesoctocog Alfa BIVV001 (DRUG).
Who is sponsoring clinical trial NCT05911763?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05911763 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05911763's enrollment target sits among peer trials
200 6th of 42 higher than 36 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI